10th Annual HealthTech Investment Forum

Feel Therapeutics, Inc. is bringing objective data and measurement into the way we diagnose, manage, and care for mental disorders, to realize the vision of Digital Precision Medicine for Mental Health. The company is backed by top-tier investors (Felicis, Anthemis, SOSV) and has partnerships with large pharmaceutical companies to develop novel digital biomarkers and bring digital health solutions to market as standalone digital treatment (DTx) or alongside medications. Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe. For more information, visit http://www.feeltherapeutics.com or contact us at info@feeltherapeutics.com.

Calciscon advances breakthrough technologies to manage a key inflammatory trigger responsible for multiple chronic diseases and aging.

CardioRenal has developed the first connected medical device allowing chronic patients to measure their blood potassium at home as easily as diabetic patients measure their glycemia. The device has been validated in a clinical study in Brussels. Commercialisation in Europe will start early 2024.

GNOMX Corp. {“GNOMX “or the “Company”), founded in October 2022, develops epigenetic diagnostic tests for infectious diseases and related conditions to improve health outcomes and reduce medical costs. This groundbreaking, patent-pending technology was developed by collaborating researchers at the Icahn School of Medicine at Mount Sinai (“ISMMS), Princeton University, Yale School of Medicine, and University of Pittsburgh School of Medicine, under a $46 million contract from the Defense Advanced Research Projects Agency (“DARPA”) The new methods discovered provide significant advantages in accuracy, specificity and versatility over existing diagnostic or prognostic test approaches.

In June 2023, GNOMX executed an option with ISMMS for a worldwide license to this disruptive technology which provides high-specificity, low cross-reactivity, and compatibility with rapid diagnostic assays that are highly advantageous compared to any existing diagnostic or prognostic technology.

GNOMX’s initial infectious disease diagnostic targets are post-COVID immune dysregulation, acute Lyme disease diagnosis, and rapid sepsis infectious agent diagnosis with antibiotic susceptibility guidance. ISMMS and GNOMX have been selected for the DARPA/NobleReach Foundation Embedded Entrepreneur Initiative that helps accelerate the transition of transformative innovations into successful products.

GNOMX is led by founder and CEO J. Mark Junewicz, Mount Sinai Innovation Partners Entrepreneur-in-Residence and life sciences investment banker. The Company’s scientific founder and Chief Scientific Officer is Stuart Sealfon, MD, the Glickenhaus Family Professor of Neurology and Director of the Center for Advanced Research on Diagnostic Assays at ISMMS, who has directed the DARPA-funded research program.

GNOMX is currently raising its first institutional financing of $15 million which will fund the company’s operations for three years. GNOMX is pursuing both equity (venture capital and strategic) and non-dilutive (US government grants and contracts) financing.

Yolia Health’s True Vision Treatment (TVT) is a safe, non-invasive, and repeatable treatment for refractive vision problems like myopia, hyperopia, and even presbyopia. TVT is self-administered by the patient in his or her own home. It employs a combination of customized gas-permeable contact lenses and specially formulated eye drops – which, when used together, safely modify the sphericity of the patient’s cornea.

After only three days of treatment with TVT, patients are freed from using reading glasses and contact lenses for up to 12 months. Patients can “refresh” or update their prescriptions at each subsequent retreatment to ensure they enjoy the best vision possible. One of TVT’s primary advantages over competitors, aside from correcting presbyopia non-invasively, is the ability to correct vision in both eyes without compromising distance vision or depth perception. On the contrary, Yolia's TVT treatment improves near and distance vision, a unique feature no other alternative can provide.

Aignostics started in 2018 within the walls of Charité Berlin and the Berlin Institute of Health, based on years of research conducted by the pathology department of Charité, TU Berlin and Fraunhofer HHI. Following initial incubation, we spun-out of Charité and BIH in 2020, and are now focusing on pioneering computational pathology for pharmaceutical research, clinical trials and CDx development.

Our strong foundation in pathology and technology, combined with our comprehensive multi-lab data access, enables us to build the best possible solutions for our global client base.

Impact Omics is a specialized genomics laboratory in the field of infectious diseases and clinical genomics. Utilizing state-of-the-art genomic technologies integrated into a proprietary workflow, we can detect all clinically relevant pathogens or genomic alterations present in a sample. Results are available within three hours and our pricing strategy sets a new standard in the industry. We offer our services to diagnostic laboratories that wish to expand their current test menu or seek cost-efficient alternatives for their current testing portfolio. We also support biotech companies with their internal pilot clinical studies by rapidly and affordably implementing custom test panels.

In the era of personalized Hematology and Oncology, the administration of targeted therapies largely depends on the diagnostics of genomic biomarkers. Moonlight AI aims at accessing this important and predictive genomic information by solely applying computer vision (AI) to scanned images from blood or bone marrow smears of the patients. These smears are collected as part of standard routine diagnostics. The algorithms developed by Moonlight AI will not only provide patients access to diagnostics and, thus, the right treatment, but they will also leverage use of continuous monitoring of patients for therapeutically relevant genomic biomarkers to evaluate response.

Based on a fundus photo, blood pressure and a lifestyle questionnaire (nutrition, smoking, alcohol consumption), the MacuTest platform predicts patients’ risk of progressing to the advanced stages of Age-related Macular Degeneration (AMD), using proprietary artificial intelligence algorithms achieving the highest predictive performance in the literature (accuracy equal to 93% at 5 years). This technology has been published in the world’s leading ophthalmology journal, Ophthalmology.

Our objective is to propose personalized monitoring aimed at reducing the risk of visual loss (reinforced ophthalmological follow-up for rapid detection and treatment of advanced forms, lifestyle recommendations, nutritional supplementation, etc.).

Another main objective of the MacuTest platform is also to raise awareness of AMD through popularized information based on the latest scientific advances.

Founded in 2020 by Pr Dr Frédéric Schuind in Fribourg, Spirecut SA is a leading Swiss medical device company focused on hand conditions, primarily carpal tunnel syndrome and trigger finger. With one in ten adults facing carpal tunnel syndrome, often requiring invasive surgeries with long recovery times, the need for innovation is clear.

Spirecut's response is the Sono-Instrument®. This single-use medical device allows for percutaneous release using ultrasound imaging, eliminating surgical incisions and ensuring swift patient recovery. Over 1,000 patients have successfully used this solution. Meeting stringent standards, Spirecut is FDA-listed and has forged key distribution agreements. CE mark is expected in early October 2023.

The Sono-Instrument® stands out due to its minimized postoperative pain, lack of surgical scars, quick recovery, suitability for outpatient operations, and reduced need for support staff.

Protecting its innovation, Spirecut holds patents for the Sono-Instrument® in major markets and has registered 'Spirecut' and 'Sono-Instrument®' as trademarks. Supported by the Swiss innovation agency, Spirecut is set to revolutionize percutaneous surgery.

ZayaAI: Revolutionizing Pathology Diagnostics

At the forefront of HealthTech, ZayaAI emerges as an innovator. Joining the 10th Annual HealthTech Investment Forum (#Sachs_HTIF) at Mövenpick Hotel Basel, we introduce our transformative vision: a genuine AI pathology wizard to amplify human experts' capabilities. Our vision? Quicker, remote, more accurate disease diagnoses.

Our Unique Proposition:
Pioneering R&D: Our research reshapes pathology's future. Every AI algorithm, discovery, focuses on transformative outcomes.

Exceptional Team: Comprising bright minds from AI and pathology, our team's expertise is our foundation.

Tangible Impact: We reduce diagnostic errors by 30%, triple pathology diagnostic speed, cut diagnostic delivery by 1-3 days, and decrease lab costs by 30%.

Our Product Suite:
Pathology Laboratory Information System (LIS): Streamlines lab processes, ensuring meticulous tracking.

Telepathology Diagnostic Platform: Overcomes geographical barriers, granting global access to diagnostic expertise.

AI Diagnostics: Specialized tools for Urothelial Carcinoma and Tuberculosis detection, promising unmatched speed and precision.

Join our journey at #Sachs_HTIF. We invite stakeholders to be part of pathology's next evolution. Let's redefine healthcare together.